**FOI Ref: 6037**

**Category(ies): Clinical - Drugs**

**Subject: Biologic medications in gastroenterology**

**Date Received: 28th September 2021**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| Q1. How many patients were treated in August 2021 (or latest available month) by the gastroenterology department with the following drugs:   * Adalimumab (any brand or biosimilar) * Infliximab (any brand or biosimilar) * Ustekinumab (Stelara) * Vedolizumab (Entyvio) * Tofacitinib (Xeljanz) * Filgotinib (Jyseleca) | 40  20  2  18  0  0 |
| Q2. How many patients were treated in August 2021 (or latest available month) for Crohn’s Disease ONLY with the following drugs:   * Adalimumab (any brand or biosimilar) * Infliximab (any brand or biosimilar) * Ustekinumab (Stelara) * Vedolizumab (Entyvio) | We are unable to obtain this level of detail |